HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (25) Citing Articles via Google Scholar Google Scholar Articles by Okabe, R. Articles by Nishizawa, Y. Search for Related Content PubMed PubMed Citation Articles by Okabe, R. Articles by Nishizawa, Y. Related Collections Proteomics and Protein Markers Endocrinology and Metabolism

Clinical Evaluation of the Elecsys ß-CrossLaps Serum Assay, a New Assay for Degradation Products of Type I Collagen C-Telopeptides

Departments of
¹ Metabolism, Endocrinology and Molecular Medicine and
² Geriatric Medicine, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
³ Hanwa Second Senboku Hospital, 3176, Fukai Kitamachi, Sakai City, Osaka 599-8271, Japan.

^aAddress correspondence to this author at: Second Department of Internal Medicine, Osaka City University Medical School, 1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. Fax 81-6-6645-3808; e-mail inaba-m{at}med.osaka-cu.ac.jp.

Background: The Elecsys ß-CrossLaps serum assay measures type I collagen degradation fragments (ß-CTx) that contain the ß-isomerized octapeptide EKAHD-ß-GGR. We investigated the analytical performance of the assay and changes in ß-CrossLaps in patients with metabolic bone diseases.

Methods: The electrochemiluminescent sandwich immunoassay uses two monoclonal antibodies directed against different regions of the linear EKAHD-ß-GGR.

Results: ß-CrossLaps (ß-CTx) immunoreactivity was stable in serum and plasma stored at 4 °C for 24 h or at room temperature for 4 h, and it did not decrease appreciably in samples stored at -30 °C for 12 weeks. Nine cycles of repeated freezing-thawing did not affect serum ß-CTx. The intra- and interassay imprecision (CVs) for four samples was 2.6% (n = 10) and 4.1% (n = 10), respectively. The mean day-to-day biological variation (CV) was 20% in 10 postmenopausal women (n = 10 days). Serum ß-CTx and osteocalcin were correlated in patients with hyperparathyroidism (r = 0.796; P <0.0001; n = 28), chronic renal failure on hemodialysis (r = 0.784; P = 0.0003; n = 16), hypoparathyroidism (r = 0.950; P = 0.0001; n = 11), and pseudohypoparathyroidism (r = 0.987; P = 0.130; n = 4). Serum ß-CTx decreased by 47.4% ± 8.8% (mean ± SD) and 60.7% ± 6.5% at 3 and 6 months, respectively, after initiation of estrogen replacement therapy in 34 women. These decreases were greater than the decreases in urinary excretion of deoxypyridinoline (31.8% ± 3.9% and 38.1% ± 4.4%, respectively) or pyridinoline cross-linked C-terminal telopeptide of type I collagen (15.9% ± 3.9% and 16.9% ± 4.6%, respectively).

Conclusions: The Elecsys ß-CrossLaps serum assay provides a potentially useful tool for assessing bone resorption state, including its response to estrogen replacement therapy.

The following articles in journals at HighWire Press have cited this article:

				Y. Maeno, M. Inaba, S. Okuno, T. Yamakawa, E. Ishimura, and Y. Nishizawa Serum Concentrations of Cross-Linked N-Telopeptides of Type I Collagen: New Marker for Bone Resorption in Hemodialysis Patients Clin. Chem., December 1, 2005; 51(12): 2312 - 2317. [Abstract] [Full Text] [PDF]

				I. R. Reid, J. Lucas, D. Wattie, A. Horne, M. Bolland, G. D. Gamble, J. S. Davidson, and A. B. Grey Effects of a {beta}-Blocker on Bone Turnover in Normal Postmenopausal Women: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5212 - 5216. [Abstract] [Full Text] [PDF]